BIEL (Bioelectronics) Short-Term Debt: $0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioelectronics Short-Term Debt?

Bioelectronics BIEL Short-Term Debt is $0.00 Mil as of . 20.

Bioelectronics's Short-Term Debt for the quarter that ended in . 20 was $0.00 Mil.

Bioelectronics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bioelectronics Short-Term Debt Related Terms

Bioelectronics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bioelectronics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioelectronics Short-Term Debt Chart

Bioelectronics Annual Data
Trend
Short-Term Debt

Bioelectronics Quarterly Data
Short-Term Debt
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Bioelectronics (BIEL) has a Short-Term Debt of $0.00 Mil as of . 20.
Is Bioelectronics' Short-Term Debt too high?
Bioelectronics' current Short-Term Debt is $0.00 Mil.
How does Bioelectronics' Short-Term Debt compare to NUVPF and ADMD?
Bioelectronics' Short-Term Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bioelectronics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioelectronics stock overvalued right now?
Bioelectronics (BIEL) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bioelectronics (BIEL), the current Short-Term Debt is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioelectronics Business Description

Address 3880 Roundtree Road, Suite 1, Jefferson, MD, USA, 21755
Bioelectronics Corp is an electroceutical company. The company develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Its product line includes Actipatch Musculoskeletal Pain Therapy, Allay menstrual pain therapy, Smart insole heel pain therapy, and Recovery RX post operative and Chronic wounds therapy. It sells its products to wholesale distributors, directly to hospitals and clinics, and to consumers. develops & commercializes electrical stimulation/neuromodulation technology. Company products include RecoveryRx, ActiPatch Musculoskeletal Pain Relief, and Others.